Market size. The reliable anchor is total spending, not a "digital health market." US national health expenditure reached an estimated $5.7 trillion in 2025, up 7.3% — a third consecutive year of 7%+ growth — and is projected to approach $9 trillion by 2034 (CMS via AHA, June 2026). [Verified for 2025 estimate; Projection thereafter.] Health price growth is expected to average only ~2.5% through 2026, meaning volume and intensity, not prices, drive the increase.
Demand and growth. Strong from a small base. US digital health startups raised $7.4 billion across 244 deals in H1 2026, up from $6.4B across 245 deals in H1 2025; median deal size rose to $14M from $12M (Rock Health, July 2026). [Verified.] Concentration is severe here too: 19 mega-deals took 45% of all capital, up from 22% in 2024 — 8% of deals absorbed nearly half the money.
Capital intensity. Moderate for software; high for anything touching clinical delivery, where you are buying clinician time and carrying medical cost.
Regulatory. Heavy: HIPAA, FDA for software-as-a-medical-device, state licensure for telehealth, and — the real barrier — reimbursement. [Analysis] Reimbursement pathway, not technology, is the primary determinant of outcome for most healthtech startups, and it is the thing founders most consistently underestimate.
Competition. High in the popular categories (mental health, weight management, scribing), low in unglamorous operational categories.
Business models. B2B2C through employers and payers; direct-to-consumer subscription; per-member-per-month; risk-bearing/value-based care (highest ceiling, highest blowup risk); and SaaS to providers. Notably, 64% of mental health and weight management startups pursue direct-to-consumer sales versus 29% industry-wide (Rock Health, July 2026).
Revenue potential. High ceiling, slow ramp. Enterprise health sales cycles of 12–24 months are normal and should be modeled as such.
Investor interest. Steady and rational, unlike 2021. Top-funded areas in H1 2026: mental health for a seventh consecutive year (Talkiatry $210M, Grow Therapy $150M) and weight management/obesity riding the GLP-1 ecosystem (eMed $200M, Nourish $100M, Midi $100M). M&A is busy: 115 acquisitions in H1 2026, with Q2's 71 deals the busiest quarter since Q3 2021; revenue cycle management is consolidating hard (Ensemble Health at $12B). Oura filed an S-1; Whoop raised $575M at $10.1B (Rock Health, July 2026).
Risks. Reimbursement changes; Medicaid enrollment and Marketplace policy shifts that CMS explicitly flags as decelerating spending growth and raising the uninsured share to a projected 9.5% by 2034; clinical liability for AI recommendations; and GLP-1 category dependence — a large share of recent funding rides one drug class.
Notable companies. Abridge, Talkiatry, Grow Therapy, Hinge Health (public, doubled from IPO price by Q2 close), Tempus (36% YoY revenue growth), Commure, Qualified Health.
Underserved opportunities. [Analysis] Back-office and administrative automation — the unsexiest, largest, most reliably fundable opportunity in healthcare, where roughly a quarter of US health spending is administrative. Also: post-GLP-1 maintenance and muscle-preservation care, which is a large cohort with no established care model; specialty care access outside metro areas; and long-term care / aging-in-place operations, which is demographically certain and technologically neglected.
Read the wider evidence
This entry is reproduced from the supplied research, with its inline source links retained. It has not been independently re-reported for this website conversion.
Read the complete chapter, source list, and methodological notes →